Literature DB >> 30352158

Role of Parkinson's Disease-Linked Mutations and N-Terminal Acetylation on the Oligomerization of α-Synuclein Induced by 3,4-Dihydroxyphenylacetaldehyde.

Vanderlei de Araújo Lima1, Lucas Alex do Nascimento1, David Eliezer2, Cristian Follmer1.   

Abstract

Identifying the mechanisms by which the presynaptic protein α-synuclein (aSyn) is associated with neurodegeneration of dopamine neurons is a major priority in the Parkinson's disease (PD) field. Studies indicate that DOPAL (3,4-dihydroxyphenylacetaldehyde), an aldehyde generated from the enzymatic oxidation of dopamine, may convert aSyn monomer into a neurotoxin via formation of covalently stabilized toxic oligomers. Herein we investigated the role of N-terminal acetylation and familial aSyn mutations (A30P, A53T, E46K, G51D, and H50Q) on DOPAL-induced oligomerization of the protein. Our results indicate that the wild-type (WT) N-terminally acetylated aSyn (Ac-aSyn) is less prone to form oligomers upon incubation with DOPAL than the non-N-terminally acetylated protein. On the other hand, familial mutants from Ac-aSyn, particularly A53T, E46K, and H50Q increased the formation of DOPAL-derived aSyn oligomers, especially large oligomers. Binding of aSyn to synaptic-like small unilamellar vesicles (SUVs) protected distinctive aSyn variants against the effects of DOPAL. While N-terminal acetylation increased the protective action of SUVs against DOPAL-induced aSyn oligomerization, A53T, A30P, and H50Q mutations in Ac-aSyn had an opposite effect. This means that PD-linked mutations may not only perturb the affinity of aSyn for membranes but also influence the formation of DOPAL-mediated oligomers. Overall, our findings provide important evidence for the existence of a connection between familial mutations of aSyn, their distinct affinity to lipid membranes, and the formation of potentially toxic oligomers of the protein mediated by DOPAL.

Entities:  

Keywords:  DOPAL; N-terminal acetylation; alpha-synuclein; familial mutations; lipid vesicles; oligomers

Mesh:

Substances:

Year:  2018        PMID: 30352158      PMCID: PMC6467814          DOI: 10.1021/acschemneuro.8b00498

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  62 in total

1.  Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy.

Authors:  K A Conway; S J Lee; J C Rochet; T T Ding; R E Williamson; P T Lansbury
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

2.  Protonless NMR experiments for sequence-specific assignment of backbone nuclei in unfolded proteins.

Authors:  Wolfgang Bermel; Ivano Bertini; Isabella C Felli; Yong-Min Lee; Claudio Luchinat; Roberta Pierattelli
Journal:  J Am Chem Soc       Date:  2006-03-29       Impact factor: 15.419

3.  N-terminal acetylation stabilizes N-terminal helicity in lipid- and micelle-bound α-synuclein and increases its affinity for physiological membranes.

Authors:  Igor Dikiy; David Eliezer
Journal:  J Biol Chem       Date:  2013-12-12       Impact factor: 5.157

4.  NMRPipe: a multidimensional spectral processing system based on UNIX pipes.

Authors:  F Delaglio; S Grzesiek; G W Vuister; G Zhu; J Pfeifer; A Bax
Journal:  J Biomol NMR       Date:  1995-11       Impact factor: 2.835

5.  Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro.

Authors:  B I Giasson; K Uryu; J Q Trojanowski; V M Lee
Journal:  J Biol Chem       Date:  1999-03-19       Impact factor: 5.157

6.  Conformational properties of alpha-synuclein in its free and lipid-associated states.

Authors:  D Eliezer; E Kutluay; R Bussell; G Browne
Journal:  J Mol Biol       Date:  2001-04-06       Impact factor: 5.469

7.  G51D α-synuclein mutation causes a novel parkinsonian-pyramidal syndrome.

Authors:  Suzanne Lesage; Mathieu Anheim; Franck Letournel; Luc Bousset; Aurélie Honoré; Nelly Rozas; Laura Pieri; Karine Madiona; Alexandra Dürr; Ronald Melki; Christophe Verny; Alexis Brice
Journal:  Ann Neurol       Date:  2013-04       Impact factor: 10.422

8.  The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia.

Authors:  Juan J Zarranz; Javier Alegre; Juan C Gómez-Esteban; Elena Lezcano; Raquel Ros; Israel Ampuero; Lídice Vidal; Janet Hoenicka; Olga Rodriguez; Begoña Atarés; Verónica Llorens; Estrella Gomez Tortosa; Teodoro del Ser; David G Muñoz; Justo G de Yebenes
Journal:  Ann Neurol       Date:  2004-02       Impact factor: 10.422

9.  The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α-synuclein, and enhances its secretion and nuclear localization in cells.

Authors:  Mohamed-Bilal Fares; Nadine Ait-Bouziad; Igor Dikiy; Martial K Mbefo; Ana Jovičić; Aoife Kiely; Janice L Holton; Seung-Jae Lee; Aaron D Gitler; David Eliezer; Hilal A Lashuel
Journal:  Hum Mol Genet       Date:  2014-04-11       Impact factor: 6.150

10.  Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro.

Authors:  Jacqueline Burré; Manu Sharma; Theodoros Tsetsenis; Vladimir Buchman; Mark R Etherton; Thomas C Südhof
Journal:  Science       Date:  2010-08-26       Impact factor: 47.728

View more
  8 in total

Review 1.  Co-translational, Post-translational, and Non-catalytic Roles of N-Terminal Acetyltransferases.

Authors:  Henriette Aksnes; Rasmus Ree; Thomas Arnesen
Journal:  Mol Cell       Date:  2019-03-13       Impact factor: 17.970

Review 2.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-18       Impact factor: 3.575

3.  Aromaticity at position 39 in α-synuclein: A modulator of amyloid fibril assembly and membrane-bound conformations.

Authors:  Fiamma A Buratti; Nicola Boeffinger; Hugo A Garro; Jesica S Flores; Francisco J Hita; Phelippe do Carmo Gonçalves; Federico Dos Reis Copello; Leonardo Lizarraga; Giulia Rossetti; Paolo Carloni; Markus Zweckstetter; Tiago F Outeiro; Stefan Eimer; Christian Griesinger; Claudio O Fernández
Journal:  Protein Sci       Date:  2022-07       Impact factor: 6.993

Review 4.  Impaired dopamine metabolism in Parkinson's disease pathogenesis.

Authors:  Anna Masato; Nicoletta Plotegher; Daniela Boassa; Luigi Bubacco
Journal:  Mol Neurodegener       Date:  2019-08-20       Impact factor: 14.195

Review 5.  Protein Misfolding and Aggregation: The Relatedness between Parkinson's Disease and Hepatic Endoplasmic Reticulum Storage Disorders.

Authors:  Francisco J Padilla-Godínez; Rodrigo Ramos-Acevedo; Hilda Angélica Martínez-Becerril; Luis D Bernal-Conde; Jerónimo F Garrido-Figueroa; Marcia Hiriart; Adriana Hernández-López; Rubén Argüero-Sánchez; Francesco Callea; Magdalena Guerra-Crespo
Journal:  Int J Mol Sci       Date:  2021-11-18       Impact factor: 5.923

Review 6.  Role of post-translational modifications on the alpha-synuclein aggregation-related pathogenesis of Parkinson's disease.

Authors:  Hajung Yoo; Jeongmin Lee; Bokwang Kim; Heechang Moon; Huisu Jeong; Kyungmi Lee; Woo Jeung Song; Junho K Hur; Yohan Oh
Journal:  BMB Rep       Date:  2022-07       Impact factor: 5.041

Review 7.  The Roles of Post-translational Modifications on α-Synuclein in the Pathogenesis of Parkinson's Diseases.

Authors:  Jiaming Zhang; Xiaoping Li; Jia-Da Li
Journal:  Front Neurosci       Date:  2019-04-18       Impact factor: 4.677

Review 8.  Alpha-Synuclein Post-translational Modifications: Implications for Pathogenesis of Lewy Body Disorders.

Authors:  Nelson de Oliveira Manzanza; Lucia Sedlackova; Raj N Kalaria
Journal:  Front Aging Neurosci       Date:  2021-06-25       Impact factor: 5.750

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.